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Background. Corticosteroids have always been an 
integral part of immunosuppressive regimens in renal 
transplantation. The primary goal of this analysis was 
to assess the safety of steroid withdrawal in our pedi-
atric renal transplant recipients receiving tacrolimus-
based immunosuppression. 
Methods. Between December 1989 and December 
1996, 82 renal transplantations were performed in pe-
diatric patients receiving tacrolimus-based immuno-
suppression. Two of these patients lost their grafts 
within 3 weeks of transplantation (and were still on 
steroids at the. time of graft loss), and were excluded 
from further analysis. Seventy-four patients (92.5%) 
were taken off prednisone a median of 5.7 months 
after transplantation. Of these 74, 56 (70%) remained 
off prednisone (OFF), and 18 (22.5%) were restarted on 
prednisone a median of 14.8 months after discontinu-
ing steroids (OFF ~ ON). 6(7.5%) were never taken-off 
prednisone (ON). The mean follow-up was 59±23 
months. 
Results. The 1-,3-, and 5-year actuarial patient sur-
vival rates in the OFF group were 100%, 98%, and 96%, 
1 Presented at the 18th Annual Meeting of the American Society 
for Transplantation, May 15-19, 1999, Chicago, IL. 
2 Thomas E. Starzl Transplantation Institute. 
.3 Division of Urologic Surgery. 
4 Pediatric Nephrology. 
5 Division of General and Vascular Surgery. 
6 Address reprint requests to: Ron Shapiro, M.D., 4th Floor Falk, 
3601 Fifth Avenue, Pittsburgh, PA 15213. 
respectively; in the OFF ~ ON group, they were 100%, 
100%, and 100%, and in the ON group, they were 100%, 
83%, and 83%. The 1-, 3-, and 5- year actuarial graft 
survival rates in the OFF group were 100%, 95%, and 
82%, respectively; in the OFF ~ ON group, they were 
100%, 89%, and 83%; and in the ON group, they were 
100%, 50%, and 33%. Two of the six graft losses in the 
OFF group, three out of four in the OFF ~ ON Group, 
and two out of five in the ON group, were to chronic 
rejection. A time-dependent Cox regression analysis 
showed that the hazard for graft failure for those who 
came and stayed off prednisone was 0.178 relative to 
those who were never withdrawn from prednisone 
(P=0.005). Patients who were 10 years of age or 
younger were withdrawn from prednisone earlier 
(median: 5 months) than those older than 10 years 
(median: 7.3 months, P=0.02). In addition, patients 
who never had acute rejection were withdrawn from 
steroids earlier (median: 5 months) than those who 
had one or more episodes of acute rejection (median: 
7.6 months, P=O.OOl). There was no effect of donor age, 
race, sex, recipient race, sex, cadaveric versus living 
donor, 48-hr graft function, panel reactive antibody, 
and total HLA mismatches or matches on the likeli-
hood of being weaned off steroids. Serum creatinine at 
most recent follow-up in the OFF group was 1.2±0.5 
mg/dl; in the OFF ~ ON group, it was 1.8±0.9 mg/dl, 
and in the ON group it was 2.0 mg/dl (P<0.003). The 
incidence of rejection in the OFF, OFF ~ ON, and ON 
groups was 39%,77%, and 100%, respectively (P<0.05). 
Conclusion. These data suggest that steroid with-
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drawal in pediatric renal transplant patients receiv-
ing tacrolimus-based immunosuppression is associ-
ated with reasonable short- and medium-term patient 
and graft survival, and acceptable renal function. Pa-
tients who discontinue and then resume steroids had 
patient and graft survival rates comparable with those 
in patients who discontinue and stay off steroids, but 
had a higher serum creatinine and a higher incidence 
of rejection. 
In spite ofthe well-established side effects associated with 
their use (1), corticosteroids have remained a part of long-
term immunosuppression after renal transplantation. With 
the introduction of tacrolimus, however, steroid withdrawal 
has been possible in some 70% of successfully transplanted 
adults and children (2-9). In the latter group, significant 
catch-up growth has been achieved, particularly in preado-
lescent children (5, 6). An important question, however, con-
cerns the outcome after steroid withdrawal in pediatric pa-
tients on tacrolimus. Although this question has been studied 
in adults (4, 7-9), it has not been investigated in detail in 
children. We looked at our pediatric renal transplant pa-
tients receiving tacrolimus-based immunosuppression and 
examined the short- and medium-term outcomes after ste-
roid withdrawal. 
PATIENTS AND METHODS 
Between December 14, 1989, and December 31, 1996, 82 renal 
transplantations under tacrolimus-based immunosuppression were 
performed in 81 pediatric patients at the Children's Hospital of 
Pittsburgh (Table 1). Two grafts were lost within 3 weeks of trans-
plantation and were excluded 'from further analysis· (the recipients 
were still on steroids at the time of graft loss). The mean recipient 
age was 10.5:':5.1 years (range: 0.7-17.9). Sixty-four (80%) were 
undergoing their first transplant, and 16 (20%) were undergoing 
their second (n=10), third (n=5), or fourth (n=l) transplants. Five 
(6%) had panel-reactive antibody (PRA) levels of 40% or higher, and 
all of them were undergoing repeat transplantation. There were 68 
(85%) Caucasian, 7 (9%) African-American, and 5 (6%) Asian recip-
ients. The causes of end-stage renal disease are listed in Table 2. 
The mean donor age was 27.9:':14.5 years (range: 0.7-50). Forty-
six (58%) kidneys were from cadaveric donors. The mean cold isch-
emia time was 27.5:':8.8 hr (range: 9.3-45.2). There were 34 (42%) 
living donors. The mean number of HLA matches and mismatches 
TABLE 1. Recipient/donor demographics 
n 80 
Recipient age (~) 10.5:':5.1 (range: 0.7-17.9) 
First transplant 64 (80%) 
Repeat transplants 16 (20%) 
Second transplant 10 (13%) 
Third transplant 5 (6%) 
Fourth transplant 1 (1%) 
PRA~40% 5 (6%) 
PRA<40% 75 (94%) 
Donor age (yr) 27.9:':14.5 (range: 0.7-50) 
Living donor 34 (42%) 
Cadaveric donor 46 (58%) 
Cold ischemia time (hr) 27.5:':8.8 (range: 9.3-45.2) 
HLA 
Match 2.9± 1.3 
Mismatch 3.0±1.3 
O-Ag mismatch 4 (5%) 
HLA-identical LRD 1 (1%) 
TABLE 2. Causes of end-stage renal disease 
Obstructive uropathy 
Congenital dysplasia 
Membranoproliferative glomerulonephritis 
Focal segmental glomerulosclerosis 
Polycystic kidney disease 
Hemolytic-uremic syndrome 
14 (17%) 
12 (15%) 
8 (10%) 
7 (9%) 
4 (5%) 
3 (4%) 
3 (4%) 
3 (4%) 
3 (4%) 
2 (2%) 
2 (2%) 
2 (2%) 
2 (2%) 
2 (2%) 
2 (2%) 
Prune belly syndrome 
Congenital hypoplasia 
Ureteral reflux 
Chronic glomerulonephritis 
Interstitial nephritis 
Pyelonephritis 
Alport's syndrome 
Cystinosis 
Hereditary nephritis 
Undetermined 11 (14%) 
was 2.9±1.3 and 3.0:':1.3, respectively. There were four (5%) O-anti-
gen mismatch cases and one (1%) HLA-identical sibling donor case. 
Immunosuppression was with tacrolimus and steroids as previ-
ously described (5, 6). Induction antilymphocyte antibody was not 
used. Eighteen patients (22%) received azathioprine. Mycophenolate 
mofetil was not used as an initial immunosuppressive agent. The 
idealized timetable for steroid withdrawal is shown in Table 3. Al-
though there were no formal a priori inclusion or exclusion criteria 
for steroid withdrawal, patients with multiple rejection episodes 
were unlikely tQ be candidates for complete withdrawal. Steroids 
were tapered and discontinued in patients who' maintained stable 
allograft function as the steroid dosage was gradually decreased. 
Steroids were restarted in recipients who experienced a rising serum 
creatinine with biopsy-proven acute rejection. Allograft failure was 
defined by return to dialysis, repeat transplantation, or death. 
Patient survival was calculated from the date of kidney transplan-
tation until death, and graft survival was calculated from the date of 
kidney transplantation until graft failure or patient death. Survival 
curves were generated using the Kaplan-Meier (product limit) 
method and were compared using the log-rank test. Values are 
presented as mean±SD. A time-dependent Cox regression analysis 
for hazard assumption was done to compare graft survival in recip-
ients who came off steroids versus those who never came off. A Cox 
time-dependent covariate z(t) was modeled, so that zU) = 1 if the 
patient was weaned off at least once, and z(t)=O if the patient was 
not weaned off by time t. 
A multivariate multiple logistic regression analysis was per-
formed to compare the effect of recipient sex, recipient race, delayed 
graft function, recipient PRA, total HLA matches, total HLA mis-
matches, donor age, and donor type (cadaveric vs. living related) on 
steroid withdrawal. The means between groups were compared by 
TABLE 3. Steroid dosing: idealized tapering schedule 
Time 
Intraoperative 
Postoperative day 1-6 
Weeks 2-3 
Weeks 4-5 
Weeks 6-7 
2 mo 
2.5 mo 
3 mo 
3.5 mo 
4mo 
5mo 
6mo 
Dose (mglkg/day) 
15-25 
3-10 to 0.3-1 
0.25-0.75 
0.2 to 0.5-0.6 
0.17-0.2 to 0.4-0.5 
0.17 to 0.25-0.3 
0.15 to 0.13-0.2 
0.13-0.1 
0.13-0.05 
0.08-0 
0.05-0 
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one-way analysis of variance. Catagorical data were analyzed by 
Pearson's chi-square method. P-values less than 0.05 were consid-
ered statistically significant. 
Until June 1994, when tacrolimus was approved by the United 
States Food and Drug Administration, all transplants were per-
formed under a protocol approved by the Human Rights Committee 
of the Children's Hospital of Pittsburgh. 
RESULTS 
The mean follow-up was 59~23 months (range: 11-103). 
Seventy-four (92.5%) patients were withdrawn from steroids 
at a median of 5.7 months after transplantation. Fifty-six 
(70%) remained off steroids, and 18 (22.5%) resumed steroids 
at median of 14.8 months after steroid withdrawal (of these 
18, 7 [39%] were eventually tapered off steroids again). Six 
(7.5%) patients never came off steroids (Tables 4 and 5). The 
overall 1-, 3-, and 5-year actuarial patient and graft survival 
rates were 100%, 97%, and 96%, and 100%, 90%, and 79%, 
respectively (Fig. 1). The 1-, 3-, and 5-year actuarial patient 
and graft survival rates for those who came and stayed off 
steroids (OFF) was 100%,98%, and 96%, and 100%, 95%, and 
82%, respectively (Figs. 2 and 3). Those who came off and 
later resumed steroids (OFF -'> ON) had a 1-, 3-, and 5-year 
actuarial patient survival of 100%, and a 1-, 3-, and 5-year 
actuarial graft survival of 100%, 89%, and 83% (Figs. 2 and 
3). In those who never came off steroids (ON), the 1-, 3-, and 
5-year actuarial patient survival was 100%, 83%, and 83%, 
and the 1-, 3-, and 5-year actuarial graft survival was 100%, 
50%, and 33% (Table 4, parts Band C, Figures 2 and 3). 
Three patients died, 1.3-3.2 years after transplantation. Two 
were off steroids; one died of pancreatitis, and one died on 
dialysis, 1.3 and 3.2 years after transplantation (the patient 
on dialysis had lost her kidney to noncompliance 1.7 years 
after transplantation). One patient who was on steroids died 
of fungal sepsis 1.3 years after transplantation. Fifteen pa-
tients lost their allografts 1.2-6.6 years after transplanta-
tion, to rejection (n=7), recurrent disease (n=5), pancreatitis 
(n=I), fungal sepsis (n=I), and noncompliance (n=1). In the 
OFF group, six grafts were lost: two to rejection, two to 
recurrent disease, one to noncompliance, and one to pancre-
atitis. In the OFf -'> ON group, four grafts were lost: three to 
TABLE 4. Demographics of steroid withdrawal 
OFF OFF ..... QN ON 
n 56 (70%) 18 (22.5%) 6 (7.5%) 
Recipient race 
Caucasian 84% 89% 83% 
Other 16% 11% 17% 
Mean recipient age (yr) 10.3:':5.6 10.1:':3.9 13.3:':3.8 
Recipient sex 
Female 29% 39% 67% 
Male 71% 61% 33% 
Delayed graft function 
Yes 4% 0% 17% 
No 96% 100% 83% 
Mean recipient PRA 5.7:':15.3 4.2:':10.6 34.5:':38.6a 
Total HLA matches 3.0:':1.3 2.3:':1.2 3.0:': 1.3 
Total HLA mismatches 2.8:': 1.4 3.5:': 1.2 2.8:':1.3 
Mean donor age (yr) 27.3:':15.2 25.9:':13.2 39.3:':5.8 
Donor type 
Cadaveric 54% 67% 67% 
Living related 46% 33% 33% 
a P=O.OOOL 
TABLE 5. Time to steroid withdrawal and episodes of acute 
rejection" 
Time to steroid withdrawal 
(mo) (mean:':SD) 
Time to restart steroids 
after withdrawal (mo) 
(mean~SD) 
Rejections 
Before withdrawal (%) 
Mer withdrawal (%) 
a *, P=NS; **, P<O.05. 
OFF 
7:':4 
39% 
OFF ..... ON 
9:':6.5* 
18 :':16 
77% 
100% 
Kaplan-l\Ieier Overall Survival 
100 (TT) (52) 
Ij (75) .. -. 
• • 00 (47) • 
~ 0 
~ ED ] 
0 Paient 
9i 40 ...• - . Gall 
'TIl 
~ JJ 
0 
1 4 
Tirre after TranspiantaijCA1 (years) 
ON 
100%** 
(21) 
(15) ... 
:) 
FIGURE 1. Overall actuarial patient and graft survival. 
~ o 
100 
40 
20 
Kaplan-Meiel':Patient Survival 
ill :-~ --
• 
• 01 Slen:icJs (rF[:6) 
• OIDl SlerocJs (rF1B) 
• 0, Sl6Ucis (11=6) 
. 
. 
O+-~--r-~~--~-r~--c-~--c 
4 
l1rre after Transplantation (years) 
FIGURE 2. Actuarial!-, 3-, and 5-year patient survival in those 
off steroids, those off and then back on steroids, and those 
never off steroids. 
rejection, and one to recurrent disease. In the ON group, five 
grafts were lost: two to rejection, two to recurrent disease, 
and one to fungal sepsis. 
There was a higher percentage of patients undergoing re-
peat transplantation in the ON group (n=5; 83%) compared 
to OFF group (n=7; 12%), and OFF -'> ON group (n=4; 22%) 
(P=O.OOI). The mean PRA was 34.5~38 for the ON group, 
5.6~15 (P=O.OOI) for the OFF group, and 4.2~10 for the OFF 
-'> ON group (P=0.002). A total of39% of patients in the OFF 
group had experienced acute rejection before steroid with-
drawal. In the OFF -'> ON group, the incidence of acute 
rejection was 77% before steroid withdrawal, and 100% after 
steroid withdrawal. In the ON group, rejection was seen in 
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FIGURE 3. Actuarial 1-, 3-, and 5-year graft survival in those 
off steroids, those off and then back on steroids, and those 
never off steroids. 
100% of patients (P<0.05) (Table 5). In recipients withJunc-
tioning allografts, the mean serum creatinine at most recent 
follow-up in the OFF group was 1.2±0.5 mg/dl, 1.8±0.9 mg/dl 
in the OFF ~ ON group, and 2.0 mg/dl in the one patient 
with a functioning kidney in the ON group (P=0.003). The 
mean tacrolimus level was 6.3±2.3 ng/ml in the 'OFF group, 
6.5±2.5 ng/ml in the OFF ~ ON group, and 13.3 ng/ml in the 
ON group. At most recent follow-up in recipients with func-
tioning allografts, 77% of the patients in the OFF group were 
off antihypertensive medications, compared with 44% in the 
OFF ~ ON group, and 0% in the ON group (Table 6; P=0.05). 
There were no statistically significant differences in the he-
matocrit, white blood cells, platelets, cholesterol and triglyc-
eride levels, and systolic and diastolic blood pressures among 
the three groups (Table 6). 
In the multivariate analysis, patients who were 10 years of 
~ge or younger were withdrawn from prednisone earlier (me-
dian: 5 months) than those older than 10 years of age (me-
dian: 7.3 months, P=0.02). By 2 years after transplantation, 
95% of patients 10 years old or younger were weaned off 
steroids, whereas 90% of patients older than 10 were weaned 
off steroids. If the patients were not weaned off steroids 
within the first 2 years, they were unlikely to be weaned off 
steroids at all. In addition, patients who never had acute 
rejection were withdrawn from steroids earlier (median: 5 
months) than those who had one or more episodes of acute 
rejection (median: 7.6 months, P=O.OOl). By 2 years after 
transplantation, 100% of those without an episode of rejec-
tion were weaned off steroids, whereas 85% of those with at 
TABLE 6. Evaluation at most recent follow-up" 
----'''------
OFF OFF -> ON ON P-value 
---.----.. -----
Creatinine (mg/dl) 1.2:'::0.5 1.8:'::0.9 2 0.003 
Hematocrit (%) 37.9:'::3.6 34.7:'::4.4 25.3 NS 
WBC (lX103/ml) 6.3:'::2.1 6.7:'::1.9 6.5 NS 
Platelets (1 X 103/ml) 203:'::56 241:'::57 175 NS 
Glucose (mg/dl) 92:'::23 97:'::23 87 NS 
Cholesterol (mg/dl) 160:'::28 157:'::18 130 NS 
Triglycerides (mgldl) 120:'::74 128:'::58 133 NS 
Systolic BP (mmHg) 112:'::16 125:'::21 140 NS 
Diastolic BP (mmHg) 73:'::11 80:'!15 80 NS 
Off antihypertensives 77% 44% 0% 0.003 
Tacrolimus level (ng/ml) 6.4:'::2.4 6.6:'::2.6 13.3 NS 
a BP, blood pressure; WBC, white blood cells. 
least one episode of rejection were weaned off steroids. Fi-
nally, there were no significant effect 9f donor age, race, sex, 
recipient race, sex, cadaveric vs. living related donor, 48-hr 
graft function, panel reactive antibodies, degree of HLA 
matching or mismatching, or immunosuppressive regiment 
(FK+steroids vs. FK+azathioprine+steroids) on the proba-
bility of being weaned off steroids. 
DlSCtJSSION 
Corticosteroids have essentially always been an integral 
part of immunosuppressive regimens in renal transplanta-
tion. In order to minimize their well-described side effects, 
there have been a number of attempts to reduce the dosage of 
corticosteroids, particularly after the advent of cyclosporine, 
when further reduction in the maintenance dosage was pos-
sible. Several trials have been undertaken to evaluate the 
outcome of corticosteroid withdrawal in patients receiving 
cyclosporine-based immunosuppression, with, in the end, not 
completely satisfactory results and an unacceptably high in-
cidence of late rejection (9-19). Most renal transplant pa-
tients still receive maintenance corticosteroids chronically. 
The primary goal of this analysis was to assess the safety 
of steroid withdrawal in our pediatric renal transplant recip-
ients receiving tacrolimus-based immunosuppression. Medi-
um-term outcomes suggest that steroid withdrawal was as-
sociated with acceptable patient and graft survival and 
stable renal function. Long-term steroid withdrawal was pos-
sible in 70% of patients, with 5-year actuarial patient and 
graft survival rates of96% and 82%, an incidence of rejection 
of 39%, and a mean serum creatinine level of 1.2±O.5 mg/dl. 
In the 22.5% of patients in whom steroids were withdrawn 
and then resumed (39% of whom eventually came back off 
steroids), the 5-year actuarial patient and graft survival 
rates were 100% and 83%, the incidence ofrejection was 77%, 
and the serum creatinine level was 1.8±0.9 mg/dl. In the 
small group of patients (7.5%) who never came off steroids, 
the 5-year actuarial patient and graft survival rates were 
83% and 33%, the incidence of rejection was 100%, and the 
serum creatinine level was 2.0 mg/dl in the remaining pa-
tient with a functioning renal allograft. In this latter group, 
the percentage of patients undergoing repeat transplantation 
was higher (83%; P=O.OOl), as was the mean PRA 
(34.5%::'::38.5%; P=O.OOI), than those in the OFF and OFF ~ 
ON groups. 
It should be emphasized that patients were not randomly 
assigned to steroid withdrawal, and patients who never came 
off steroids had a number of risk factors, including repeat 
transplantation, sensitization, and acute rejection. The mail1. 
questions for us concerned the safety of steroid withdrawal 
and, perhaps more importantly, the outcomes in patients 
who were withdrawn from and then resumed steroids. Five-
year patient and graft survival rates were essentially iden-
tical in the OFF and the OFF ~ ON groups, but the incidence 
of rejection and the mean serum creatinine were higher in 
the OFF ~ ON group, and these findings are of concern with 
regard to longer-term follow-up. We have previously reported 
on the benefits of steroid withdrawal in children, including 
significant catch-up growth, a low incidence of hypertension, 
and normal cholesterol levels (5, 6). Unfortunately, there are 
no useful markers to identify patients who can be safely 
withdrawn from steroids. 
To summarize, long-term steroid withdrawal in pediatric 
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renal transplant patients receiving tacrolimus-based immu-
nosuppression was associated with reasonable long-term pa-
tient and graft survival and renal function. Patients who 
discontinued and then resumed steroids had comparable pa-
tient and graft survival rates, but a higher incidence of re-
jection and higher serum creatinine levels. Patients who 
never came off steroids had the worst outcomes. In order to 
identify which pediatric renal transplant recipients are most 
likely to benefit from steroid withdrawal, prospective, ran-
domized trials with well-defined criteria will likely be neces-
sary. 
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